Development and Validation of the Elecsys Anti-SARS-CoV-2 Immunoassay as a Highly Specific Tool for Determining Past Exposure to SARS-CoV-2.


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
22 09 2020
Historique:
received: 03 07 2020
accepted: 30 07 2020
pubmed: 5 8 2020
medline: 6 10 2020
entrez: 5 8 2020
Statut: epublish

Résumé

The Elecsys Anti-SARS-CoV-2 immunoassay (Roche Diagnostics) was developed to provide accurate, reliable detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We evaluated sensitivity, specificity, cross-reactivity, and agreement with a vesicular stomatitis virus-based pseudoneutralization assay for the Elecsys Anti-SARS-CoV-2 immunoassay. Sensitivity and agreement between Elecsys Anti-SARS-CoV-2 immunoassay and pseudoneutralization assay measurements were evaluated using samples from patients with PCR-confirmed SARS-CoV-2 infection, a majority of whom were hospitalized. Specificity was evaluated using samples from routine diagnostic testing/blood donors collected before December 2019 and thus deemed negative for SARS-CoV-2-specific antibodies. Cross-reactivity was evaluated using samples containing a wide range of potentially cross-reacting analytes, purchased from commercial vendors. For sensitivity and specificity, point estimates and 95% confidence intervals (CIs) were calculated. Agreement between the Elecsys Anti-SARS-CoV-2 immunoassay and the pseudoneutralization assay was calculated. The sensitivity of the Elecsys Anti-SARS-CoV-2 immunoassay in patients with prior PCR-confirmed SARS-CoV-2 infection was 99.5% (95% CI, 97.0 to 100.0%) at ≥14 days post-PCR confirmation. Overall specificity (

Identifiants

pubmed: 32747400
pii: JCM.01694-20
doi: 10.1128/JCM.01694-20
pmc: PMC7512151
pii:
doi:

Substances chimiques

Antibodies, Viral 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Validation Study

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2020 Muench et al.

Références

Clin Chem. 2020 Nov 1;66(11):1405-1413
pubmed: 32777031
Stat Med. 2004 Aug 30;23(16):2537-50
pubmed: 15287083
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
J Hosp Infect. 2020 Mar;104(3):246-251
pubmed: 32035997
N Engl J Med. 2020 Mar 26;382(13):1268-1269
pubmed: 32109011
Eur Respir J. 2020 Aug 27;56(2):
pubmed: 32430429
Euro Surveill. 2020 Mar;25(11):
pubmed: 32209163
Nat Rev Immunol. 2020 Jun;20(6):339-341
pubmed: 32317716
Lancet Infect Dis. 2020 May;20(5):515-516
pubmed: 32213336
Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Clin Chem. 2020 Aug 1;66(8):1055-1062
pubmed: 32402061
Clin Infect Dis. 2020 Nov 19;71(16):2027-2034
pubmed: 32221519
Clin Transl Immunology. 2020 May 06;9(5):e01136
pubmed: 32382418
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Emerg Microbes Infect. 2020 Dec;9(1):727-732
pubmed: 32196410
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
J Clin Epidemiol. 2005 Aug;58(8):859-62
pubmed: 16018921
Nat Med. 2020 Jul;26(7):1033-1036
pubmed: 32398876
J Infect. 2020 Jul;81(1):147-178
pubmed: 32209385
Clin Microbiol Infect. 2020 Oct;26(10):1386-1394
pubmed: 32603801
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32381641
Expert Rev Vaccines. 2016;15(3):295-311
pubmed: 26641943
Viruses. 2020 Feb 25;12(3):
pubmed: 32106567
New Microbes New Infect. 2020 Apr 14;35:100679
pubmed: 32322401
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Clin Infect Dis. 2020 Jul 28;71(15):778-785
pubmed: 32198501
Trends Immunol. 2020 May;41(5):355-359
pubmed: 32249063
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
J Clin Virol. 2020 Aug;129:104480
pubmed: 32505777
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32229605
Lancet Infect Dis. 2020 May;20(5):565-574
pubmed: 32213337
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
J Med Virol. 2020 May;92(5):495-500
pubmed: 32022276
Clin Chem. 2020 Jul 1;66(7):875-877
pubmed: 32343775
Rev Med Virol. 2020 May;30(3):e2107
pubmed: 32267987
Immunity. 2020 Jun 16;52(6):971-977.e3
pubmed: 32413330
J Med Virol. 2020 May;92(5):464-467
pubmed: 32031264
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):1063-1071
pubmed: 33534090
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430

Auteurs

Peter Muench (P)

Roche Diagnostics GmbH, Penzberg, Germany.

Simon Jochum (S)

Roche Diagnostics GmbH, Penzberg, Germany.

Verena Wenderoth (V)

Roche Diagnostics GmbH, Penzberg, Germany.

Beatus Ofenloch-Haehnle (B)

Roche Diagnostics GmbH, Penzberg, Germany.

Michael Hombach (M)

Roche Diagnostics International Ltd, Rotkreuz, Switzerland michael.hombach@roche.com.

Matthias Strobl (M)

Roche Diagnostics GmbH, Penzberg, Germany.

Henrik Sadlowski (H)

Labor Berlin-Charité Vivantes Services GmbH, Berlin, Germany.

Christopher Sachse (C)

KRH Labor GmbH, Hannover, Germany.

Giulia Torriani (G)

Department of Molecular Medicine and Microbiology, Faculty of Medicine, Université de Genève, Geneva, Switzerland.

Isabella Eckerle (I)

Department of Molecular Medicine and Microbiology, Faculty of Medicine, Université de Genève, Geneva, Switzerland.
Hôpitaux Universitaires Genève, Geneva, Switzerland.
Division of Infectious Diseases, Department of Medicine, Université de Genève, Geneva, Switzerland.
Laboratory of Virology, Division of Laboratory Medicine, Université de Genève, Geneva, Switzerland.
Center for Emerging Viral Diseases, Université de Genève, Geneva, Switzerland.

Alexander Riedel (A)

Roche Diagnostics GmbH, Penzberg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH